IC50 Values Of Compounds Research Articles

Purification of Xanthine Oxidase Enzyme and Investigation of Its Immobilization with Glutaraldehyde

In this study, the xanthine oxidase (XO) enzyme was purified by affinity chromatography technique using Sepharose-4B-L-tyrosine-4-aminobenzamidine gel and its immobilization with glutaraldehyde was investigated. Using ammonium sulfate precipitation and affinity gel, xanthine oxidase was purified 643.04-fold in an 11.5% yield. The purity of the enzyme was checked by SDS polyacrylamide gel electrophoresis and a single band around 150 kDa was observed. KM (the Michaelis constant) and VMax (the asymptotic reaction velocity at infinite substrate concentration) of the enzyme were determined at 1.67x10-4 M and 0.56 U/mL.min respectively by using a xanthine compound as a substrate. The in vitro effects of NH4F, NH4Cl, CaCl2, ZnCl2, HgCl2, Hg(NO3)2.H2O compounds and commercially named colchicum dispert, commonly used in the treatment of gout disease in the clinic, were investigated. The IC50 values of compounds showing inhibition effects were determined. Afterward, XO was immobilized with glutaraldehyde. The highest XO activity was observed in the sample of the immobilized enzyme at a rate of 6% glutaraldehyde. The kinetic constants (KM and VMax) of the immobilized enzyme were determined as 5.18x10-4 M and 0.73 U mL-1 min-1 respectively. These values revealed that the catalytic activity of the free enzyme was higher than the immobilized enzyme.

Isolation, In Vitro and In Silico Anti-Alzheimer and Anti-Inflammatory Studies on Phytosteroids from Aerial Parts of Fragaria × ananassa Duch.

Based on the pharmacological importance of different species of fragaria, this research was carried out for the isolation of bioactive compounds from Fragaria × ananassa. Using the conventional gravity column chromatography followed by small analytical column purification, two major components were isolated from the plant materials. The structures of both compounds (1 and 2) were accurately confirmed with GC-MS analysis by comparison of the fragmentation pattern within the library of the instrument. Further, the NMR analysis was also used to supplement the structural evidence. Compound 1 was observed to be 4,22-cholestadien-3-one, while compound 2 was identified as stigmast-4-en-3-one. Both compounds were evaluated for anticholinesterase, COX/LOX inhibitions and antioxidant assays. Compound 1 exhibited the IC50 values of 20.29, 27.35, 10.70, 80.10 and 7.40 μg/mL against acetylcholinesterase, butyrylcholinesterase, COX-2, COX-1 and 5-LOX, respectively. Similarly, the IC50 values of compound 2 against the same targets were 14.51, 10.65, 8.45, 109.40 and 8.71 μg/mL. Similarly, both compounds were less potent in ABTS and DPPH targets with IC50 values in the range of 185.83–369.86 μg/mL. Despite the low potencies of these compounds in antioxidant targets, they can be considered as supplementary targets in Alzheimer and inflammation. The molecular docking studies for the in vitro anti-Alzheimer and anti-inflammatory targets were also performed, which showed excellent binding interactions with the respective target proteins. In conclusion, the isolated phytosteroids from Fragaria × ananassa were evaluated scientifically for anti-Alzheimer and anti-inflammatory activities using in vitro and molecular docking approaches.

In Vitro Characterization of Inhibitors for Lung A549 and Leukemia K562 Cell Lines from Fungal Transformation of Arecoline Supported by In Silico Docking to M3-mAChR and ADME Prediction.

The search for anticancer drugs is of continuous interest. Arecoline is an alkaloid with anticancer activity. Herein, the metabolism of arecoline through fungal transformation was investigated for the discovery of potential anticancer drugs with higher activity and selectivity. Compounds 1–5 were isolated, and their structures were fully elucidated using various spectroscopic analyses, including 1D and 2D NMR, ESIMS, and HRESIMS. This is the first report for the isolation of compounds 1 and 2. An MTT assay was performed to determine the cytotoxic activity of arecoline and its metabolites in vitro using non-small-cell lung cancer A549 and leukemia K562 cell lines compared to staurosporine and doxorubicin as positive controls. For the non-small-cell lung A549 cell line, arecoline hydrobromide, staurosporine, and doxorubicin resulted in IC50 values of 11.73 ± 0.71 µM, 10.47 ± 0.64 µM, and 5.05 ± 0.13 µM, respectively, while compounds 1, 3, and 5 exhibited IC50 values of 3.08 ± 0.19 µM, 7.33 ± 0.45 µM, and 3.29 ± 0.20 µM, respectively. For the leukemia K562 cell line, the IC50 values of arecoline hydrobromide, staurosporine, and doxorubicin were 15.3 ± 1.08 µM, 5.07 ± 0.36 µM, and 6.94 ± 0.21 µM, respectively, while the IC50 values of compounds 1, 3 and 5 were 1.56 ± 0.11 µM, 3.33 ± 0.24 µM, and 2.15 ± 0.15 µM, respectively. The selectivity index value of these compounds was higher than 3. These results indicated that compounds 1, 3, and 5 are very strong cytotoxic agents with higher activity than the positive controls and good selectivity toward the tested cancer cell lines. Cell cycle arrest was then studied by flow cytometry to investigate the apoptotic mechanism. Docking simulation revealed that most compounds possessed good binding poses and favorable protein-ligand interactions with muscarinic acetylcholine receptor M3-mAChR protein. In silico study of pharmacokinetics using SwissADME predicted compounds 1–5 to be drug-like with a high probability of good oral bioavailability.

Three New Acrylic Acid Derivatives from Achillea mellifolium as Potential Inhibitors of Urease from Jack Bean and α-Glucosidase from Saccharomyces cerevisiae.

(1) Background: Achillea mellifolium belongs to a highly reputed family of medicinal plants, with plant extract being used as medicine in indigenous system. However, limited data is available regarding the exploitation of the medicinal potential of isolated pure compounds from this family; (2) Methods: A whole plant extract was partitioned into fractions and on the basis of biological activity, an ethyl acetate fraction was selected for isolation of pure compounds. Isolated compounds were characterized using different spectroscopic techniques. The compounds isolated from this study were tested for their medicinal potential using in-vitro enzyme assay, coupled with in-silico studies; (3) Results: Three new acrylic acid derivatives (1–3) have been isolated from the ethyl acetate fraction of Achillea mellifolium. The characterization of these compounds (1–3) was carried out using UV/Vis, FT-IR, 1D and 2D-NMR spectroscopy (1H-NMR, 13C-NMR, HMBC, NOESY) and mass spectrometry. These acrylic acid derivatives were further evaluated for their enzyme inhibition potential against urease from jack bean and α glucosidase from Saccharomyces cerevisiae, using both in-silico and in-vitro approaches. In-vitro studies showed that compound 3 has the highest inhibition against urease enzyme (IC50 =10.46 ± 0.03 μΜ), followed by compound 1 and compound 2 with percent inhibition and IC50 value of 16.87 ± 0.02 c and 13.71 ± 0.07 μΜ, respectively, compared to the standard (thiourea-IC50 = 21.5 ± 0.01 μΜ). The investigated IC50 value of compound 3 against the urease enzyme is two times lower compared to thiourea, suggesting that this compound is twice as active compared to the standard drug. On the other hand, all three compounds (1–3) revealed mild inhibition potential against α-glucosidase. In-silico molecular docking studies, in combination with MD simulations and free energy, calculations were also performed to rationalize their time evolved mode of interaction inside the active pocket. Binding energies were computed using a MMPBSA approach, and the role of individual residues to overall binding of the inhibitors inside the active pockets were also computed; (4) Conclusions: Together, these studies confirm the inhibitory potential of isolated acrylic acid derivatives against both urease and α-glucosidase enzymes; however, their inhibition potential is better for urease enzyme even when compared to the standard.

Abstract 5452: Discovery of a novel seleno-leonurine analog as a potential therapeutic for ovarian cancer

Abstract Leonurine is an active alkaloid that is extracted from Traditional Chinese Medicine Herba leonuri. It has been reported to be beneficial for cardiovascular diseases, including atherosclerosis, acute and chronic myocardial infarction (MI), and ischemic stroke. Mao et al. illustrated that leonurine could up-regulate the expression of phosphorylated p38 and down-regulate phosphorylated Akt expression through inhibiting mitochondrial pathway, thus suppressing the proliferation and promoting lung cancer cell apoptosis. Accumulating evidence suggest that the extract of Leonurus sibiricus transgenic roots could induce apoptosis in different grades of human glioma cells and significantly promotes cisplatin sensitivity in cervical cancer cells via repressing cell proliferation, improving intrinsic cell apoptosis and inhibiting the expression of P-Gp and MRP1 protein, which has potential therapeutic value in cervical cancer treatment. In the present study, we designed and synthesized several selenium analogs of leonurine and their cytotoxicity were assessed using four different ovarian cancer cell lines viz. OVCAR-3, OVCAR-10, ES2, and drug resistant HeyA8 cells. Compared to the control and leonurine group, compound 834 inhibited the ovarian cancer cell viability in dose- and time-dependent manner. The IC50 values of compound 834 was 4.6 µM, 3.8 µM, 6.2 µM, and 5.7 µM for OVCAR-3, HeyA8, OVCAR-10, and ES2 cells, respectively, while for leonurine the IC50 value was >500 µM for 48 h treatment. To further acquaint the effect of 48 h treatment on cell proliferation, we performed trypan blue cell viability assay, trypan blue dye exclusion assay, Annexin V/7-AAD, Caspase 3/7 apoptosis assays and Western blotting of apoptotic proteins involved in apoptosis. Compound 834 significantly induced apoptosis in OVCAR-3 and HeyA8 cells in dose dependent manner. Upregulation of several apoptotic proteins, as evident by Western blot, suggested that 834 causes induction of apoptotic pathways efficiently. Further, the cell cycle analysis showed a significant arrest of OVCAR-3 and HeyA8 cells in the S-phase, which was further confirmed by the analysis of cyclin A2, cyclin-E1, p21 and p27 proteins expression. Conclusively, our research revealed that leonurine analog 834 significantly induces apoptosis in ovarian cancer cells via repressing cell proliferation, improving intrinsic cell apoptosis and inhibiting the expression of several signaling proteins, which has potential therapeutic value in ovarian cancer treatment. Citation Format: Asif Raza, Jacek Krzeminski, Shantu Amin, Arun Sharma. Discovery of a novel seleno-leonurine analog as a potential therapeutic for ovarian cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5452.

Phytochemistry, anti-diabetic and antioxidant potentials of Allium consanguineum Kunth

AimThe study was planned to investigate the phytochemicals, antidiabetic and antioxidant studies of A. consanguineum.MethodsThe preliminary studies were performed on crude extract and different solvent fractions. Based on the potency, the chloroform fraction was semi-purified to phyto-fractions CHF-1 – 5. Furthermore, CHF-3 was subjected to isolation of pure compounds using column chromatography. The α-glucosidase, α-amylase and antioxidant assays (DPPH, ABTS, H2O2) were performed on all samples. The in-vivo experiments on compounds 1 and 2 were also performed using oral glucose tolerance test. Docking studies were performed on α-glucosidase and α-amylase targets.ResultsAmong all fractions, the chloroform fraction exhibited excellent activities profile giving IC50 values of 824, 55, 117, 58 and 85 μg/ml against α-glucosidase, α-amylase, DPPH, ABTS and H2O2 targets respectively. Among the five semi-purified chloroform phyto-fractions (CHF-1-5), CHF-3 was the leading fraction in activities giving IC50 values of 85.54, 61.19 and 26.58 μg/ml against α-glucosidase, α-amylase and DPPH respectively. Based on the overall potency and physical amount of CHF-3, it was subjected to purification to get compounds 1 and 2. The two compounds were also found potent in in-vitro activities. The observed IC50 values for compound 1 were 7.93, 28.01 and 6.19 μg/ml against α-glucosidase, α-amylase and DPPH respectively. Similarly, the compound 2 exhibited IC50 of 14.63, 24.82 and 7.654 μg/ml against α-glucosidase, α-amylase and DPPH respectively. Compounds 1 and 2 were potent in decreasing the blood glucose levels in experimental animals. Compounds 1 and 2 also showed interactions with the respective enzymes with molecular docking.ConclusionsWe can conclude that A. Consanguineum is a rich source of natural antidiabetic agents. Bioguided isolation of compound 1 and 2 showed potential inhibitions in all tested in-vitro antidiabetic targets. Further, both the compounds were also able to decrease the blood glucose levels in experimental animals.

Pseudo-sapogenin DQ 3-Maleate Derivative Induces Ovarian Carcinoma Cell Apoptosis via Mitochondrial Pathway.

In the present study, four novel ginsenosides fatty acid and aromatic acid derivatives were designed and synthesized, and their cytotoxic effects on human ovarian carcinoma cells (SKOV3) were assessed using the 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. The results demonstrated that all derivatives inhibited SKOV3 cell growth, and Compound 3 showed the most outstanding anti-proliferative effect on SKOV3 cells. The IC50 value of Compound 3 was 33.8 ± 2.21 µM, less than half of that of cis-platinum (70.1 ± 7.64 µM). Subsequent analysis revealed that Compound 3 could promote SKOV3 cell apoptosis, and the percentage of apoptotic cell population increased with increasing Compound 3 concentrations. In addition, the expression ratios of Bax/Bcl-2, cleaved-Caspase-3/Caspase-3 and cleaved-Caspase-9/Caspase-9 were gradually elevated in Compound 3-treated SKOV3 cells compared with control cells. Furthermore, translocation of Bax to mitochondria was associated with the release of Cytochrome C. Molecular docking analysis revealed three hydrogen-bonds existed in Compound 3 with poly(ADP-ribose)polymerase (PARP) receptor (PDB code: 5DSY), which may be the target of the anti-ovarian cancer effect of Compound 3. Altogether, our study indicates that Compound 3 induces SKOV3 cell apoptosis via reactive oxygen species (ROS)-dependent mitochondrial pathway, and can serve as an anti-cancer agent for treating ovarian carcinoma.

A new phenylpropanoid-substituted epicatechin from the rhizome of Smilax china

A new phenylpropanoid-substituted epicatechin, (2 R,3S,9R)-methyl {2-(3,4-dihydroxyphenyl)-3,5,8a,4a-tetrahydroxy-3,4-dihydro-2H,12H-pyrano[2,3-α]xanthen-12-yl}acetate (1) was isolated from the rhizome of Smilax china, along with twelve known compounds (2 − 13), which were isolated from the Smilax genus for the first time. On the basis of chemical evidences and spectral data analysis (UV, ECD, 1 D and 2 D-NMR, HR-ESI-MS), the structures of compound 1 was elucidated. Furthermore, all compounds have been tested for their inhibitory effects on NO production in LPS-induced RAW 264.7 cells, and compounds 6, 7, 11 and 13 have obvious inhibitory effect, in which the IC50 value of compound 7 reached 11.63 ± 1.29 μM. Through target screening and molecular docking, we can speculate that compound 7 may exert its anti-inflammatory effect by binding to MAPKAP kinase 2 and Leukocyte Proteases Cathepsin G & Chymase.

Synthesis, characterization, and enzyme inhibition activities of 4-(methylthio)-N-propylaniline-phenylpiperazine and sulfonamide derivatives

We have combined piperazine, thioether, and sulfonamide structural motifs in a mainframe for biological evaluation. The synthesis involved the alkylation of 4-aminothioanisole with chloroalkyl piperazine followed by treatment of resulting amino piperazine 3 with various aryl sulfonyl chlorides. All target compounds (3–7) were characterized by 1H, 13C, HRMS, and IR. In addition, all obtained piperazine derivatives were evaluated for their tyrosinase and pancreatic lipase enzyme inhibitory activities. The enzyme analyses showed that some of the piperazine derivatives possess effective tyrosinase inhibitions with IC50 values of 18.7 ± 1.8 for compound 6 and 24.7 ± 3.4 for compound 4, which is close to the IC50 value of kojic acid (19.2 ± 1.2 µM). On the other hand, the synthesized compounds showed low IC50 values in the range from 46.2 ± 4.9 to 86.6 ± 8.4 µM against pancreatic lipase enzyme. Compound 3 was found to be the most effective pancreatic lipase inhibitor among the synthesized compounds. The IC50 value of compound 3 (46.2 ± 4.9 µM) was determined slightly lower than the IC50 value of orlistat (49.5 ± 3.2 µM), pointing to more effective inhibition. Finally, in silico molecular docking interactions of piperazine derivatives were evaluated for their tyrosinase and pancreatic lipase enzyme inhibitory activities using Chimera molecular visualization and AutoDock Vina software.

Bioactive La(III), Er(III), Yb(III), Ru(III), and Ta(V) complexes of new organometallic Schiff base: Preparation, structural characterization, antibacterial, anticancer activities, and MOE studies

AbstractBioactive complexes [La(L)(H2O)3Cl]Cl2.2H2O (1), [Er(L)(H2O)3Cl]Cl2 (2), [Yb(L)(H2O)2Cl2]Cl.4H2O (3), [Ru(L)(H2O)2Cl2]Cl.H2O (4), and [Ta(L)(H2O)Cl5] (5) have been prepared from 2‐acetylferrocene derivative Schiff base (L) and characterized with different spectroscopic tools. Infrared (IR) spectral data proved the action of the ligand as a neutral bidentate Schiff base, coordinating via N‐azomethine and N‐pyrazole. Ta(V)‐complex was eight‐coordinated complex, whereas others were six‐coordinated complexes. Molar conductance results showed that La(III) and Er(III) chelates were 1:2 electrolytes, Yb(III) and Ru(III) chelates were 1:1 electrolytes, and Ta(V) chelate was non‐electrolyte. Thermal behavior of all compounds was characterized by thermogravimetric analysis/differential thermogravimetric analysis (TG/DTG) curves with mass loss related to dehydration, coordination, and decomposition steps. Growth inhibitory effect and IC50 values of compounds toward MCF‐7 cancer cell line were measured, and the data revealed that all complexes showed higher anticancer activity than free ligand. The lowest IC50 value was 4.5 μg/mL for La(III) and Ru(III) complexes. Furthermore, almost complexes showed good activities against Escherichia coli, Pseudomonas aeruginosa, Bacillus subtilis, and Staphylococcus aureus species with inhibition zone diameter in the range of 10–15 mm/mg. While, they had no antifungal activities against Candida albicans and Aspergillus flavas species. Finally, the strong binding affinity of ligand and its complexes with different protein receptors was confirmed by MOE studies.

Novel hybrid isoindole-1,3(2H)-dione compounds containing a 1H-tetrazole moiety: Synthesis, biological evaluation, and molecular docking studies.

In this study, novel hybrid isoindole-1,3(2H)-dione compounds (10 and 11) carrying a 1H-tetrazole moiety were synthesized, characterized and their inhibitory properties against xanthine oxidase (XO) and carbonic anhydrase isoenzymes (hCA I and hCA II) were investigated. Allopurinol for XO and acetazolamide for carbonic anhydrase isoenzymes were used as positive standards in inhibition studies. In addition, compounds 8 and 9, which were obtained in the intermediate step, were also investigated for their inhibition effects against the three enzymes. According to the enzyme inhibition results, hybrid isoindole-1,3(2H)-dione derivatives 10 and 11 showed significant inhibitory effects against all three enzymes. Surprisingly, compound 8, containing a SCN functional group, exhibited a greater inhibitory effect than the other compounds against hCA I and hCA II. The IC50 values of compound 8 against hCA I and hCA II were found to be 3.698 ± 0.079 and 3.147 ± 0.083 µM, respectively. Compound 8 (IC50 = 4.261 ± 0.034 μM) showed higher activity than allopurinol (IC50 = 4.678 ± 0.029 μM) and the other compounds against XO, as well. These results clearly show the effect of the SCN group on the inhibition. In addition, in silico molecular docking studies were performed to understand the molecular interactions between each compound and enzymes, and the results were evaluated.

Development of penipanoid C-inspired 2-benzoyl-1-methyl-2,3-dihydroquinazolin-4(1H)-one derivatives as potential EGFR inhibitors: Synthesis, anticancer evaluation and molecular docking study

A novel class of penipanoid C-inspired 2-benzoyl-1-methyl-2,3-dihydroquinazolin-4(1H)-ones (3a-3f) and 1-methyl-2-(3,4,5-trihydroxybenzoyl)-2,3-dihydroquinazolin-4(1H)-one derivatives (10–15) was successfully synthesized using the I2/DMSO method. The newly synthesized compounds were characterized and tested for cytotoxicity against three cancer cell lines: HepG2 (human liver), MCF7 (human breast), and HCT116 (human colorectal). The majority of the tested molecules had a considerable cytotoxic impact, in some cases larger than doxorubicin. Furthermore, the inhibitory effect of six compounds (10–15) against epidermal growth factor receptor (EGFR) kinases were investigated, with three compounds (10, 11 and 12) showing good IC50 values. The IC50 values for compounds 10 and 12 against wildtype EGFR were 0.222 and 0.172 µM, respectively. Compound 12 had good enzyme inhibitory efficacy with 71.30 and 421.53 µM for the EGFR L858R and T790M mutants, respectively, which is more effective than the positive control, erlotinib, and close to lapatinib. The results of the biological screening were also confirmed by docking studies, which predicted the potential binding interactions of the target compounds with the EGFR active sites. Compounds 10 and 12 appear to be interesting lead compounds with the potential to be developed as anticancer agents, based on the findings.

Identification of novel antiplatelet agents by targeting Glycoprotein VI: A combined virtual screening study

Cardiovascular diseases are the primary reason for deaths in the world. However, antiplatelet drugs in the market have limitations in use because of the risk of increased bleeding and other side effects that impair primary homeostasis. Therefore, safe and effective antithrombotic drugs are needed for the treatment of plaque formation in blood vessels. Glycoprotein VI (GPVI) is a platelet major collagen receptor and a target for potent and safe antithrombotic therapy. We designed this study based on the molecular interaction pattern of previously published GPVI receptor antagonists within the reported binding site. We selected sixteen hit compounds from a large chemical database that contains>6 million in-stock compounds by following a combined virtual screening. Then, we evaluated their inhibitory effects on platelet aggregation induced by GPVI receptor agonists (collagen, collagen related peptide (CRP), convulxin) and the most potent platelet agonist, thrombin, in vitro by using washed human platelets. IC50 values of compounds 1 and 2 are, respectively, 0.35 μM and 1.01 μM for collagen, 0.80 μM and 1.92 μM for CRP, 195.2 and 7.24 μM for convulxin and 81.38 and 51.74 μM for thrombin. We identified compounds 1 and 2 as the most promising antiplatelet agents out of sixteen compounds. Additionally, compounds 1 and 2 may serve as promising starting points and shed light on the design of new, potent and selective GPVI receptor antagonists.

Methyl benzoate derivatives as inhibitors of pentose phosphate pathway, which promotes cancer progression and drug resistance: An in silico study supported by in vitro results

The pentose phosphate pathway (PPP), whose products are vital in biosynthetic events, is targeted in the treatment of many diseases such as cancer and malaria. The objective of this study was to identify new PPP inhibitors. The inhibition effects of methyl 4-amino benzoates on glucose 6-phosphate dehydrogenase (G6PD) and 6-phosphogluconate dehydrogenase (6PGD) were analyzed through in vitro experiments and molecular docking studies were used to estimate inhibition mechanisms. IC50 values of compounds were found between 100.8 and 430.8μM for G6PD and 206 and 693.2μM for 6PGD. Molecular docking analysis showed that compound 1 was found the most effective inhibitor against hG6PD and compound 4 had the highest inhibitory potency against h6PGD with the estimated binding energy of -6.71 and -7.61kcal/mol, respectively. In conclusion, it was determined that in vitro and in silico outcomes of the study were highly correlated with each other. The structure of these benzoates may aid in the development of drugs that target the PPP.

Myrsinane-type diterpenes from Euphorbia gedrosiaca with cell growth inhibitory activity and apoptotic effects on melanoma cancer cells

Phytochemical analysis of Euphorbia gedrosiaca Rech.f., Aellen & Esfand., an Iranian endemic spurge, afforded the isolation of four myrsinane types diterpene polyesters. Two new compounds (1–2) were based on a myrsinane skeleton while the others (3–4) were known diterpenes based on a cyclomyrsinane backbone. Their chemical structures were elucidated by spectroscopic methods, including 1D and 2D NMR and HRESIMS. The isolated compounds were tested to evaluate their cell growth inhibitory activity and apoptotic effects on melanoma cell lines, B16F10 and A375. The IC50 values for compounds 1–4 were 58.45, 55.43, 86.52 and 82.27 μM, respectively, on B16F10, and 20.66, 21.88, 36.21 and 39.87 μM, respectively, on A375 cells. Non-treated cells were used as negative control (100% cell growth) and 5 nM Taxol were considered as a positive control.

Synthesis of novel oxadiazole derivatives and their cytotoxic activity against various cancer cell lines.

Caffeic acid (CA), ferulic acid (FA) and caffeic acid phenethyl ester (CAPE) have a broad anticancer effect on various cell lines. In this study, nine ferulic and caffeic acid-based 1,2,4 and 1,3,4 oxadiazole molecular hybrids were synthesized and their cytotoxic activity was evaluated mainly against Glioblastoma (GBM) cell lines. Compounds 1 and 5 exhibited the highest inhibitory activity against three different GBM cell lines (LN229, T98G, and U87), without toxicity to healthy human mesenchymal stem cells (hMSC). In addition, their cytotoxicity was also evaluated against three additional cancer cell lines and more inhibitory results were found than GBM cell lines. The IC50 values of compound 5 in U87, T98G, LN229, SKOV3, MCF7, and A549 cells were determined as 35.1, 34.4, 37.9, 14.2, 30.9, and 18.3 μM. In the light of biological activity studies, the developed compounds have a high potential to lead studies for the development of new drug candidates for the treatment of cancer.

SCOPOLETIN AS A MARKER COMPOUND FROM FERMENTED Morinda citrifolia FRUITS EXTRACT: POTENTIAL α-GLUCOSIDASE INHIBITOR AND ANTIOXIDANT COMPOUNDS

Morinda citrifolia juice has long been used as a traditional herbal medicine in Indonesia to treat various diseases, including lowering blood sugar levels. However, the compounds responsible for this activity have not been widely studied. This research aimed to isolate the marker compounds from fermented M. citrifolia juice extract based on bioassay guidelines of antidiabetic activity and reduction of DPPH. Separation and purification of the ethyl acetate fraction yielded two, namely compounds 1 and 2. The chemical structures of these marker compounds, identified as scopoletin (1) and quercetin (2), were elucidated by LCMS Spectrometry and NMR analyses. The IC50 values of compounds 1 and 2 were respectively 61.93 and 21.65 μM for α-glucosidase, with 844.06 and 35.23 μM for DPPH free radical scavenger effect. Based on these results, scopoletin and quercetin can be used as quality control biomarkers of products produced from fermented M. citrifolia juice extract.

Synthesis, In Vitro and In Silico Anticancer Activity of New 4-Methylbenzamide Derivatives Containing 2,6-Substituted Purines as Potential Protein Kinases Inhibitors.

A novel class of potential protein kinase inhibitors 7–16 was synthesized in high yields using various substituted purines. The most promising compounds, 7 and 10, exhibited inhibitory activity against seven cancer cell lines. The IC50 values for compounds 7 and 10 were 2.27 and 2.53 μM for K562 cells, 1.42 and 1.52 μM for HL-60 cells, and 4.56 and 24.77 μM for OKP-GS cells, respectively. In addition, compounds 7 and 10 dose-dependently induced the apoptosis and cell cycle arrest at G2/M phase, preventing the cell division of OKP-GS cells. Compounds 7, 9, and 10 showed 36–45% inhibitory activity against PDGFRα and PDGFRβ at the concentration of 1 μM. Molecular modeling experiments showed that obtained compounds could bind to PDGFRα as either type 1 (compound 7, ATP-competitive) or type 2 (compound 10, allosteric) inhibitors, depending on the substituent in the amide part of the molecule.

Cholesterol‐Based Conjugates: Synthesis, Characterization and In Vitro Biological Studies

AbstractBacterial infections, malaria and cancer are causes of high death rates. Most of the drugs used to combat these diseases suffer from drug resistance, poor absorption and bioavailability and toxic side effects. Cholesterol is a sterol abundantly found in the human body and forms part of the structure and organisation of cell membranes. It is readily available, has functional groups that can be easily modified, and is affordable. In this research, different known therapeutic agents (anticancer, antimalarial and antibacterial) were conjugated to cholesterol and the synthesized compounds were characterized using FTIR, 1H and 13C NMR, and Mass Spectroscopy, followed by in vitro antiplasmodial, antibacterial and anticancer studies. Thirteen compounds were successfully synthesized. Compound 10, containing curcumin and cholesterol was the most effective against all the Gram‐positive strains of bacteria while compounds 9–11, containing either curcumin or zidovudine scaffold were effective against all the strains of bacteria. Compound 13, containing pyrimethamine and cholesterol showed good antiplasmodial activity with 97.75 and 97.83 % inhibition of asexual parasite proliferation at 20 and 10 μg/mL concentrations, respectively. In vitro cytotoxicity of the synthesized compounds on HeLa (cervical cancer) cells revealed IC50 values for compounds 2 (7.559 μg/mL), 3 (5.840 μg/mL), 5 (1.44 mg/mL), 7 (4.308 μg/mL) and 11 (3.295 μg/mL) confirming promising anticancer activity.

Novel Pyridine Bioisostere of Cabozantinib as a Potent c-Met Kinase Inhibitor: Synthesis and Anti-Tumor Activity against Hepatocellular Carcinoma.

Two novel bioisosteres of cabozantinib, 3 and 4, were designed and synthesized. The benzene ring in the center of the cabozantinib structure was replaced by trimethylpyridine (3) and pyridine (4), respectively. Surprisingly, the two compounds showed extremely contrasting mesenchymal–epithelial transition factor (c-Met) inhibitory activities at 1 μM concentration (4% inhibition of 3 vs. 94% inhibition of 4). The IC50 value of compound 4 was 4.9 nM, similar to that of cabozantinib (5.4 nM). A ligand-based docking study suggested that 4 includes the preferred conformation for the binding to c-Met in the conformational ensemble, but 3 does not. The anti-proliferative activity of compound 4 against hepatocellular carcinoma (Hep3B and Huh7) and non-small-cell lung cancer (A549 and H1299) cell lines was better than that of cabozantinib, whereas 3 did not show a significant anti-proliferative activity. Moreover, the tumor selectivity of compound 4 toward hepatocellular carcinoma cell lines was higher than that of cabozantinib. In the xenograft chick tumor model, compound 4 inhibited Hep3B tumor growth to a much greater extent than cabozantinib. The present study suggests that compound 4 may be a good therapeutic candidate against hepatocellular carcinoma.